Some existing biomarkers such as prostate-specific antigen (PSA) may be useful in PCa screening, but its utility is hampered by its poor specificity, leading to over-diagnosis and over-treatment, which limits its application [114,115,116]. The gene discussed is KLK3; the disease is posterior cortical atrophy.